Oleclumab is an experimental immunotherapy drug that works by blocking a new anti-cancer target called CD73. This allows the body to increase the number of immune cells available to attack and destroy cancer cells.
Durvalamab (Imfinzi®) is Health Canada-approved immunotherapy that is used in the treatment of lung cancer. Another member of this class of drugs is called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a molecule called PD-L1 which enables the immune system to better recognize and destroy cancer cells.
This study will investigate the safety and effectiveness of Durvalumab and Oleclumab when used in combination for patients with advanced kidney cancer.
Patients will also have the “methylation status” of their DNA assessed to determine if this can help predict whether patients will respond positively or negatively to this type of treatment. DNA Methylation is a feature of DNA that can help researchers determine whether it is “on” and in use by the cell, or “off” and not being used by the cell. This can be done using a standard blood test.
This is a single-group study, so there is no randomization, no placebo, and all patients will receive treatment.
- All subtypes eligible
- Cancer has spread or cannot be removed by surgery
- Must have previously received at least one immunotherapy treatment
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Albiruni Razak||LocationToronto, ON||Trial StatusNot yet recruiting|